公开(公告)号：US09340521B2

公开(公告)日：2016-05-17

申请号：US13845466

申请日：2013-03-18

Applicant: GREEN CROSS CORPORATION

Inventor： Soongyu Choi ,  Jae Eun Kim ,  Kwang-Seop Song ,  Suk Ho Lee ,  Kisoo Park ,  Hee Jeong Seo ,  Min Ju Kim ,  Eun-Jung Park ,  So Ok Park ,  Younggyu Kong ,  Hyunku Kang ,  Ickhwan Son ,  Myung Eun Jung ,  Man-Young Cha ,  Hyun Jung Kim ,  Jun Sung Lee ,  Mi-Soon Kim ,  Min Woo Lee ,  Kinam Lee

IPC: C07D309/10 ,  C07D407/04 ,  C07D409/04 ,  C07D409/14

CPC classification number: C07D309/10 ,  C07D407/04 ,  C07D409/04 ,  C07D409/14

Abstract: The present invention relates to a method for dual inhibition of sodium-dependent glucose cotransporter 1 (SGLT1) and sodium-dependent glucose cotransporter 2 (SGLT2) present in the intestine and kidney by using the compound of formula I or a pharmaceutically acceptable salt or a prodrug thereof: wherein ring A, ring B, X and Y have the same meanings as defined in the specification.

Abstract translation: 本发明涉及通过使用式I化合物或其药学上可接受的盐或其药学上可接受的盐或其药学上可接受的盐或其药学上可接受的盐或其盐 其前药：其中环A，环B，X和Y具有与说明书中定义相同的含义。

公开(公告)号：US10239873B2

公开(公告)日：2019-03-26

申请号：US15080068

申请日：2016-03-24

Applicant: GREEN CROSS CORPORATION

Inventor： Soongyu Choi ,  Kwang-Seop Song ,  Hee Jeong Seo ,  Sang-ho Ma ,  Eun-Jung Park ,  Younggyu Kong ,  So Ok Park ,  Kisoo Park ,  Ickhwan Son ,  Min Ju Kim ,  Man-Young Cha ,  Mi-Soon Kim ,  Sang Mi Kang ,  Dong Hyuk Jang ,  Jangwon Hong

IPC: C07D471/04 ,  C07D519/00 ,  C07D487/04

Abstract: Provided are 7-azaindole or 4,7-diazaindole derivatives as an IKKε (I-kappa-B kinase epsilon) and TBK1 (TANK-binding kinase 1) inhibitor. The 7-azaindole or 4,7-diazaindole derivative effectively inhibits IKKε and TBK1, and thus is useful not only as an anticancer agent for the treatment of various cancers including colorectal cancer, breast cancer, CNS cancer, colon cancer, non-small cell lung cancer, kidney cancer, prostate cancer, ovarian cancer, uterus cancer, stomach cancer, liver cancer, skin cancer, lung cancer, brain cancer, bladder cancer, esophageal cancer, pancreatic cancer, thyroid cancer, head and neck cancer, squamous cell carcinoma, osteosarcoma, B-cell or T-cell lymphoma, acute or chronic leukemia and multiple myeloma, but as a therapeutic agent for chronic inflammation.

公开(公告)号：US09856216B2

公开(公告)日：2018-01-02

申请号：US15134987

申请日：2016-04-21

Applicant: GREEN CROSS CORPORATION

Inventor： Soongyu Choi ,  Eun-Jung Park ,  Hee Jeong Seo ,  Younggyu Kong ,  Ickhwan Son ,  Sang-ho Ma ,  Man-Young Cha ,  Mi-Soon Kim ,  Kisoo Park

IPC: C07D209/14 ,  C07D209/48 ,  C07D209/46 ,  C07D417/04 ,  C07D403/04 ,  C07D401/04 ,  C07D403/14 ,  C07D409/12 ,  C07D405/12 ,  C07D409/04 ,  C07D413/04 ,  C07D409/14 ,  C07D403/12 ,  C07D405/06 ,  C07D409/06 ,  C07D471/04 ,  C07D217/24 ,  C07D401/12

CPC classification number: C07D209/46 ,  C07D209/48 ,  C07D217/24 ,  C07D401/04 ,  C07D401/12 ,  C07D403/04 ,  C07D403/12 ,  C07D403/14 ,  C07D405/04 ,  C07D405/06 ,  C07D405/12 ,  C07D409/04 ,  C07D409/06 ,  C07D409/12 ,  C07D409/14 ,  C07D413/04 ,  C07D417/04 ,  C07D471/04

Abstract: Provided is a compound of formula (I) as a TNIK (Traf2- and NCK-interacting kinase), IKKε (I-kappa-B kinase epsilon) and TBK1 (TANK-binding kinase 1) inhibitor; the compound according to the present invention effectively inhibits TNIK, IKKε and TBK1, and thus is useful not only as an anticancer agent for the treatment of various cancers including colorectal cancer, breast cancer, CNS cancer, colon cancer, non-small cell lung cancer, kidney cancer, prostate cancer, ovarian cancer, uterus cancer, stomach cancer, liver cancer, skin cancer, lung cancer, brain cancer, bladder cancer, esophageal cancer, pancreatic cancer, thyroid cancer, head and neck cancer, squamous cell carcinoma, osteosarcoma, B-cell or T-cell lymphoma, acute or chronic leukemia and multiple myeloma, but as a therapeutic agent for chronic inflammation.

公开(公告)号：US10294207B2

公开(公告)日：2019-05-21

申请号：US15083503

申请日：2016-03-29

Applicant: GREEN CROSS CORPORATION

Inventor： Soongyu Choi ,  Kisoo Park ,  Hee Jeong Seo ,  Eun-Jung Park ,  Younggyu Kong ,  Ickhwan Son ,  Sang-ho Ma ,  Kwang-Seop Song ,  Min Ju Kim ,  So Ok Park ,  Man-Young Cha ,  Mi-Soon Kim ,  Sang Mi Kang ,  Dong Hyuk Jang ,  Jangwon Hong

IPC: C07D231/56 ,  C07D401/12 ,  C07D403/12 ,  C07D405/12 ,  C07D409/12 ,  C07D409/14 ,  C07D413/12 ,  C07D413/14 ,  C07D495/04 ,  C07D409/04 ,  C07D417/12

Abstract: Provided is pyrazole derivatives as a TNIK (Traf2- and NCK-interacting kinase), IKKε (I-kappa-B kinase epsilon) and TBK1 (TANK-binding kinase 1) inhibitor; the pyrazole derivative according to the present invention effectively inhibits TNIK, IKKε and TBK1, and thus is useful not only as an anticancer agent for the treatment of various cancers including colorectal cancer, breast cancer, CNS cancer, colon cancer, non-small cell lung cancer, kidney cancer, prostate cancer, ovarian cancer, uterus cancer, stomach cancer, liver cancer, skin cancer, lung cancer, brain cancer, bladder cancer, esophageal cancer, pancreatic cancer, thyroid cancer, head and neck cancer, squamous cell carcinoma, osteosarcoma, B-cell or T-cell lymphoma, acute or chronic leukemia and multiple myeloma, but as a therapeutic agent for chronic inflammation.